EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Significance of p53 overexpression in bone marrow biopsies from patients with bone marrow failure: Aplastic anemia, hypocellular refractory anemia, and hypercellular refractory anemia



Significance of p53 overexpression in bone marrow biopsies from patients with bone marrow failure: Aplastic anemia, hypocellular refractory anemia, and hypercellular refractory anemia



Annals of Hematology 77(6): 261-264



Among patients with bone marrow failure, differentiating acquired aplastic anemia (AA) from hypocellular refractory anemia (hypo RA) can be a difficult and challenging task. Morphological, cytochemical, immunocytochemical, and cytogenetic studies may provide tools for discriminating between both entities. In addition, differences in the pattern of proliferation and apoptosis of bone marrow cells in AA and in the myelodysplastic syndrome have been reported. Because of the correlation between p53 and apoptosis, we examined the overexpression of p53 on bone marrow biopsies in RA and AA. Our study included 14 patients with hypo RA, 14 patients with hypercellular (hyper) RA, ten patients with classic acquired AA, and 37 hematologically normal individuals. p53 was overexpressed in eight (57%) hypo RA patients and 11 (79%) hyper RA patients. All normal individuals and patients with AA showed no overexpression of p53 in their marrow. These results were statistically significant p<0.01 (AA vs hypo RA), p<0.001 (AA vs hyper RA), while the difference between hypo RA and hyper RA was not statistically significant. We conclude that p53 overexpression in bone marrow biopsies is a valuable tool for studying bone marrow failure and may provide additional information to help differentiate hypo RA from acquired AA.

(PDF emailed within 0-6 h: $19.90)

Accession: 011359022

Download citation: RISBibTeXText

DOI: 10.1007/s002770050455



Related references

Significance of p53 overexpression in bone marrow biopsies from patients with bone marrow failure: aplastic anemia, hypocellular refractory anemia, and hypercellular refractory anemia. Annals of Hematology 77(6): 261-264, 1999

Pattern of p53 expression in bone marrow biopsies from patients with bone marrow failure Fanconis anemia, hypocellular refractory anemia and acquired aplastic anemia. Blood 90(10 SUPPL 1 PART 2): 12B-13B, Nov 15, 1997

P53 expression in marrow biopsies from patients with hypercellular refractory anemia, hypocellular refractory anemia and aplastic anemia. Laboratory Investigation 76(1): 135A, 1997

P53 overexpression in bone marrow biopsies in refractory anemia and aplastic anemia: Impact of antibody selection. Leukemia Research 24(11): 975-977, November, 2000

Aplastic Anemia and Refractory Anemia with the HLA-DR15 Haplotype A Bone Marrow Failure Syndrome Caused by Common Immune-Mechanisms. Blood 100(11): Abstract No 877, November 16, 2002

A case of hypoplastic acute leukemia which transformed naturally from hypercellular bone marrow to hypocellular with reference to the atypical aplastic anemia. Japanese Journal of Clinical Hematology 22(11): 1743-1750, 1981

Refractory anemia with hypercellular bone marrow and preleukemia. Medizinische Klinik 71(48): 2127-2135, 1976

p53 overexpression in refractory anemia. An immunohistochemical analysis of bone marrow biopsies. Haematologica 84(4): 377-378, 1999

Comparative multi-color flow cytometric analysis of cell surface antigens in bone marrow hematopoietic progenitors between refractory anemia and aplastic anemia. Leukemia Research 24(4): 359-366, April, 2000

p53 protein overexpression in bone marrow biopsies of patients with Shwachman-Diamond syndrome has a prevalence similar to that of patients with refractory anemia. Archives of Pathology & Laboratory Medicine 126(4): 452-455, 2002

Clinically relevant possibilities and limits of differential diagnosis of megaloblastic anemia and myelodysplastic syndrome - refractory anemia type in bone marrow biopsies. Vnitrni Lekarstvi 62(9): 692-697, 2016

Clinical Significance of the Bone Marrow Morphological Differences in the Differential Diagnosis of Megaloblastic Anemia and Refractory Anemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 24(3): 801-805, 2016

Prognostic value of multilineage dysplasia and bone marrow histology in the FAB subgroups of refractory anemia and refractory anemia with ringed sideroblasts and possible relevance in the new WHO proposal. Leukemia Research 27(Supplement 1): S19-S20, 2003

Bone marrow changes in patients with refractory aplastic anemia treated by recombinant GM-CSF. Hematologic Pathology 4(2): 79-85, 1990

Analysis of the T-cell clonotype in the bone marrow of immune-mediated aplastic anemia Identification of a T-cell clone that preferentially proliferates in the bone marrow of a cyclosporine-dependent aplastic anemia patient. Blood 84(10 SUPPL 1): 9A, 1994